THOUSAND OAKS, Calif., Nov. 23, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that CVS Health will provide preferred access to Repatha ® (evolocumab) through its CVS/caremark commercial ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

To view the multimedia assets associated with this release, please click: http://www.multivu.com/players/English/74140513-amgen-repatha-glagov-study. The GLAGOV study ...

An FDA approval for Amgen's cholesterol-reducing Repatha opens its use to for heterozygous familial hypercholesterolemia, a condition that affects 1 in 250 worldwide but often goes undiagnosed.

A biotech drug used to treat inherited high cholesterol that last year saw its price reduced will soon only be available at that lower price. Thousand Oaks, California-based Amgen said Thursday that ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

THOUSAND OAKS, Calif. (Nov. 13, 2020) - Amgen (NASDAQ:AMGN) today announced a new analysis from the Repatha® (evolocumab) cardiovascular (CV) outcomes study (FOURIER) that evaluated the effectiveness ...

Both Repatha and Praluent are used to treat high cholesterol and reduce the risk of certain cardiovascular events. The drugs also have different approved uses in adults and children. Repatha and ...

Some common side effects of Repatha (evolocumab) include a runny nose, a sore throat, upper respiratory infections, and back pain. Serious side effects of Repatha include diabetes, angioedema (rapid ...

Amgen (NASDAQ: AMGN) announced that CVS Health (NYSE:CVS) will provide preferred access to Repatha® (evolocumab) through its CVS/caremark commercial formularies. "Ensuring access to Repatha for ...